CompaniesACIC Pharmaceuticals

ACIC Pharmaceuticals

active

Brantford, ON, Canada

Founded 1973

Website

About

Contract Manufacturing of Small Molecules and APIs

Areas of Focus

Categories

Contract ManufacturingContract Manufacturing

Clinical Trials (51)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

12,315

By Phase

PHASE4: 4PHASE3: 19PHASE2: 18PHASE2/PHASE3: 4EARLY_PHASE1: 1PHASE1/PHASE2: 1PHASE1: 1

By Status

COMPLETED: 28TERMINATED: 9RECRUITING: 5WITHDRAWN: 3NOT_YET_RECRUITING: 2ENROLLING_BY_INVITATION: 2ACTIVE_NOT_RECRUITING: 1APPROVED_FOR_MARKETING: 1

Clinical Trials Pipeline50 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Today

NCT00087542

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2004

Completion: Dec 31, 2005

NCT01518309

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 17, 2004

Completion: May 2, 2013

NCT01518309

NCT00628420

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

Phase: Phase 1

Role: Collaborator

Start: Jan 31, 2005

Completion: Oct 31, 2007

NCT00361166

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2005

Completion: Mar 31, 2007

NCT00477672

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Jul 31, 2009

NCT00490516

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Feb 29, 2008

NCT00550238

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2007

Completion: May 30, 2018

NCT00550238

NCT00658567

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2008

Completion: Dec 31, 2009

NCT01174004

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2010

Completion: Nov 30, 2012

NCT02035553

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2013

Completion: Oct 27, 2016

NCT02970292

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 26, 2016

Completion: Jun 25, 2019

NCT02970305

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 4, 2016

Completion: Oct 28, 2019

NCT02992132

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2016

Completion: Feb 16, 2018

NCT03018340

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Phase: Phase 2

Role: Lead Sponsor

Start: Dec 31, 2016

Completion: Oct 31, 2018

NCT03121586

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2017

Completion: May 30, 2024

NCT03121586

NCT03118947

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 23, 2017

Completion: Feb 25, 2019

NCT03152292

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Phase: N/A

Role: Lead Sponsor

Start: Mar 30, 2017

Completion: Mar 8, 2021

NCT03325556

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 27, 2017

Completion: Oct 30, 2019

NCT03482882

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 9, 2018

Completion: Jul 24, 2019

NCT03575052

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Phase: Phase 3

Role: Lead Sponsor

Start: May 21, 2018

Completion: May 6, 2022

NCT03623321

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 17, 2018

Completion: May 5, 2023

NCT03623321

NCT03968159

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 25, 2019

Completion: May 29, 2020

NCT05240339

Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

Phase: N/A

Role: Collaborator

Start: Apr 25, 2019

Completion: Dec 31, 2023

NCT05240339

NCT04000009

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 6, 2019

Completion: Feb 22, 2021

NCT04164758

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 23, 2019

Completion: Sep 25, 2020

NCT04181723

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 6, 2019

Completion: Oct 28, 2021

NCT04179266

Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache

Phase: Phase 1/2

Role: Lead Sponsor

Start: Nov 20, 2019

Completion: May 25, 2020

NCT04279314

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 29, 2020

Completion: Aug 19, 2022

NCT04292223

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Phase: Phase 4

Role: Lead Sponsor

Start: Feb 10, 2020

Completion: Apr 26, 2022

NCT04531982

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 5, 2020

Completion: Feb 19, 2024

NCT03947216

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Phase: Phase 2

Role: Collaborator

Start: Oct 23, 2020

Completion: Jun 17, 2024

NCT04776746

Open-Label Extension Study of Trofinetide for Rett Syndrome

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 8, 2020

Completion: Jun 30, 2023

NCT04855240

Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 29, 2021

Completion: Mar 14, 2022

NCT05008835

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 20, 2021

Completion: Nov 16, 2022

NCT04988867

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

Phase: Phase 2/3

Role: Lead Sponsor

Start: Sep 22, 2021

Completion: May 31, 2023

NCT05523895

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Phase: Phase 2/3

Role: Lead Sponsor

Start: Aug 9, 2022

Completion: Sep 27, 2024

NCT05555615

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Phase: Phase 2/3

Role: Lead Sponsor

Start: Nov 2, 2022

Completion: Feb 14, 2025

NCT04809116

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Phase: Phase 4

Role: Collaborator

Start: Dec 15, 2022

Completion: Dec 15, 2023

NCT05357612

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Phase: Phase 4

Role: Collaborator

Start: Jan 23, 2023

Completion: Aug 31, 2026

NCT05796167

Pimavanserin for Sleep in Parkinson Disease

Phase: Early Phase 1

Role: Collaborator

Start: Jan 27, 2023

Completion: Jun 24, 2024

NCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

Phase: Phase 2/3

Role: Lead Sponsor

Start: Nov 14, 2023

Completion: Feb 29, 2028

NCT06159673

NCT06173531

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 27, 2023

Completion: Nov 30, 2025

NCT06420297

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 11, 2024

Completion: Jun 30, 2029

NCT06420297

NCT06194799

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 23, 2024

Completion: May 31, 2029

NCT06194799

NCT05895513

Pimavanserin and Aggression and Social Cognition.

Phase: Phase 2

Role: Collaborator

Start: Aug 1, 2024

Completion: Jan 31, 2028

NCT03994965

The Sub-Sero Study

Phase: Phase 2

Role: Collaborator

Start: Dec 1, 2024

Completion: Dec 4, 2024

NCT05999240

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

Phase: Phase 2

Role: Collaborator

Start: Apr 28, 2025

Completion: May 15, 2026

NCT07029581

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 6, 2025

Completion: Mar 31, 2028

NCT07095465

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 31, 2025

Completion: Mar 31, 2029

NCT07153835

Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study

Phase: Phase 4

Role: Collaborator

Start: Sep 1, 2025

Completion: Jul 31, 2026

Hover over trial bars to see details

Recent Trials

NCT07153835Collaborator

Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study

PHASE4Not yet recruiting

505 participants

Started: Sep 1, 2025 · Completed: Jul 31, 2026

NCT07095465Lead Sponsor

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

PHASE3Not yet recruiting

126 participants

Started: Aug 31, 2025 · Completed: Mar 31, 2029

NCT07029581Lead Sponsor

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

PHASE2Recruiting

180 participants

Started: Aug 6, 2025 · Completed: Mar 31, 2028

NCT05999240Collaborator

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

PHASE2Recruiting

30 participants

Started: Apr 28, 2025 · Completed: May 15, 2026

NCT03994965Collaborator

The Sub-Sero Study

PHASE2Withdrawn

Started: Dec 1, 2024 · Completed: Dec 4, 2024

View all 51 trials →

Locations (1)

Headquarters

Brantford, ON, Canada

Map

Loading map...